ICU Medical (ICUI) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Executive insights and capital allocation

• Recent insider stock purchases reflect confidence in future earnings and value creation, with ongoing personal investment in equity and options.

• Capital allocation remains focused on organic growth, innovation, and shareholder returns, with limited appetite for new M&A unless highly compelling.

• Leverage reduction to around 2x is a priority, with expectations to reach this target in the next year based on current cash flow forecasts.

• Divestiture of IV solutions via a joint venture with Otsuka has streamlined the portfolio, improving margins and freeing resources for core segments.

Business segment performance and strategy

• Consumables segment has compounded at 5–6% annually, driven by strong end-market demand, demographic trends, product quality, and recent IV solution shortages.

• IV systems are experiencing above-market growth due to competitive wins, product modernization, and market refresh cycles triggered by industry recalls.

• Home care is identified as a strategic adjacency, leveraging high market share in ambulatory pumps and exploring connectivity and data-driven opportunities.

• Vital Care division, now smaller post-JV, faces flat to negative growth, with ongoing evaluation of scale, innovation, and potential divestiture.

Innovation, regulatory, and competitive landscape

• Significant investment in new product development, especially in infusion pumps, with recent FDA approvals and ongoing 510(k) filings expected to drive growth.

• Integration of hardware and software platforms aims to deliver a unified, connected solution across care settings, matching or exceeding competitor offerings.

• Regulatory scrutiny remains high, seen as a barrier to entry and a driver for continuous compliance and quality improvement.

• Home care connectivity initiatives seek to create new revenue streams by integrating patient data and monitoring into infusion events.